As South Africa grapples with the aftermath of recent civil unrest and violent looting, Cipla’s manufacturing plant in Durban – which was sadly hit during the turmoil – stands ready to reopen and resume operations .
Some media have falsely claimed that the facility burned down, when it was in fact vandalized on July 13, 2021. Fortunately, none of the more than 500 Cipla employees working at the plant were injured in the incident. .
After the looting incident, Cipla put in place adequate emergency measures, such as operating its global supply chain and other manufacturing sites, to ensure the continuity of the supply of medicines, especially for key therapeutic areas such as antiretrovirals for people living with HIV. From an inventory perspective, Cipla also had a good amount of buffer stock in its other distribution centers across the country, which helped mitigate any possible supply disruptions.
Cipla South Africa CEO Paul Miller said: “The staff at Cipla have shown an indomitable spirit and have worked tirelessly to ensure that we can resume operations as quickly as possible at this facility. We were also fortunate to have the support of various other actors in the local community who helped in the aftermath of this incident.
“Whatever the circumstances, we are committed to our ‘Take Care of Life’ philosophy, and the rapid turnaround time to get this site back up and running is proof of that,” Miller said. Cipla employed five subcontractors to expedite the intensive cleaning operation and repair process at this Good Manufacturing Practices (GMP) certified facility.
Localized industry is one of the most effective stimulators of economic growth and job creation. Therefore, as a proudly South African pharmaceutical manufacturing company, Cipla is focused on an “Africa for Africa” strategy. Cipla’s footprint spans the entire African continent: in addition to the Durban factory, Cipla also has a factory in Johannesburg and another manufacturing facility in Uganda. It aims to equip various regions with its own manufacturing capacities and invests in upgrading the technological capabilities of these factories to improve production capacity, stimulate digital innovation and ensure patients have uninterrupted access to quality medicines and affordable.
By actively creating employment and skills development opportunities, the result is more than just economic growth; it is to offer better health to patients and to ensure the socio-economic well-being of communities.
Manufacturing industry in particular stimulates more economic activity in society than any other sector. This globally recognized multiplier effect creates employment opportunities, demand for resources, investment and development opportunities. This invaluable stimulating effect on economic growth is attributed to the many important links between manufacturing and most other sectors of the economy.
Therefore, in addition to ensuring the continuity of drug supply, it was also essential that Cipla resume operations as quickly as possible at the affected manufacturing facility.
Founded in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics and a deepening portfolio in our home markets of India, South Africa, North America and the United States. main regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urological, cardiological, anti-infective and CNS segments are well known.
Our 46 manufacturing sites around the world produce more than 50 dosage forms and more than 1,500 products using advanced technology platforms to serve our more than 80 markets. Cipla is ranked third in pharmaceuticals in India, third in private pharmaceutical market in South Africa, and among the most widely distributed generic players in the United States.
For more than eight decades, making a difference for patients has inspired all aspects of Cipla’s work. Our paradigm shift offering of triple HIV antiretroviral therapy for less than a dollar a day in Africa in 2001 is widely recognized as having helped put inclusiveness, accessibility and affordability at the center of the movement. HIV.
As a responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its goal of “Caring for Life” and deep-rooted community ties wherever it operates make it a partner of choice for global health organizations, peers and all stakeholders.
About Cipla South Africa:
Cipla Medpro South Africa (Pty) Limited (Cipla Medpro) is a wholly owned subsidiary of Cipla Limited, India (Cipla) and the third largest private sector pharmaceutical company in South Africa. Through Cipla’s philosophy of “Caring for Life”, Cipla Medpro produces world-class medicines at affordable prices for the public and private sectors, thus advancing health care for all South Africans.
For more information visit www.cipla.co.za